More than $12K in product stolen from Sacramento County beauty business after break-in, owner says
Baby found dead in Lodi street, officials say
Michael Andretti hands over control of race team to business partner. Formula 1 plans in limbo
Saudi Arabia forms global alliance to push for Israeli-Palestinian two-state solution
Israel-Hamas war latest: Israel carries out attack on Hezbollah headquarters in Beirut
As the Ukraine war enters a critical period, the EU moves ahead without the US
Facing a possible strike at US ports, Biden administration urges operators to negotiate with unions
US Gulf Coast oil prices to take center stage as exports dominate
This MIT grad found a big, bold, and fun way to get girls of color working in STEM
Oklahoma couple's engagement photo captures stormy backdrop
What to watch this weekend
Maggie Smith, beloved actress, dies at 89
(Reuters) - AbbVie is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen and Cerevel Therapeutics, Bloomberg News reported on Wednesday, citing people with knowledge of the matter.
The sale is expected to be announced as soon as Thursday, following fixed-income investor calls on Wednesday, the sources said, requesting anonymity as the discussions were private, according to the report.
The size of the offering is subject to change and will be determined on the day of the sale.
AbbVie did not immediately respond to Reuters' request for a comment.
In December, AbbVie announced back-to-back acquisitions - a $8.7 billion plan to buy Cerevel and its $10.1 billion deal for ImmunoGen, which was recently completed.
AbbVie has since said that it plans to focus on smaller deals to support its growth through the next decade.
On Tuesday, the drugmaker named Robert Michael to replace Richard Gonzalez as CEO in July.
(Reporting by Sriparna Roy and Bhanvi Satija in Bengaluru; Editing by Sherry Jacob-Phillips)
